Targeted ADCs OncoPrecision is developing first-in-class antibody-drug conjugates with a focus on CD64 targeting for monocytic AML and CMML, presenting a clear selling point for partnerships or licensing discussions around targeted oncology therapeutics and hematologic malignancies.

PMA Platform Their Patient Micro-Avatar platform leverages AI-enhanced discovery and patient-derived biology datasets to guide target identification and therapeutic design, offering a potential collaboration angle for biopharma companies seeking accelerated, data-driven development pipelines.

Phase and IND ONC001 is advancing through IND-enabling studies, signaling near-term feasibility for collaboration on clinical-stage or translational opportunities, including co-development or milestone-driven funding discussions.

Financial Signals With seed funding already raised and annual revenue in the low to mid single digits, OncoPrecision represents an opportunity for early strategic investments, grant support, or convertible/debt financing aligned with a growing biotech in precision oncology.

Industry Fit Operating in precision oncology with a focus on hematologic malignancies and solid tumors, the company aligns well with potential partners in oncology biotech, pharma, contract research, and technology providers offering AI, data pipelines, or ADC development support.